PURPOSE: The aim of this study was to describe the outcome in patients with head-and neck-squamous cell carcinoma (HNSCC) followed up without neck dissection (ND) after concomitant chemoradiotherapy (CRT) based on computed tomography (CT) response. The second objective was to establish CT characteristics that can predict which patients can safely avoid ND. METHODS AND MATERIALS: Between 1998 and 2007, 369 patients with node-positive HNSCC were treated with primary CRT at our institution. After a clinical and a radiologic evaluation based on CT done 6 to 8 weeks after CRT, patients were labeled with a complete neck response (CR) or with a partial neck response (PR). RESULTS: The median follow-up was 44 months. The number of patients presenting with N3, N2, or N1 disease were 54 (15%), 268 (72%), and 47 (13%), respectively. After CRT, 263 (71%) patients reached a CR, and 253 of them did not undergo ND. Ninety-six patients reached a PR and underwent ND. Of those, 34 (35%) had residual disease on pathologic evaluation. A regression of the diameter of ≥ 80% and a residual largest diameter of 15 mm of nodes had negative pathologic predictive values of 100% and 86%, respectively. The 3-year regional control and survival rates were not different between patients with CR who had no ND and patients with PR followed by ND. CONCLUSION: Node-positive patients presenting a CR as determined by CT evaluation 6 to 8 weeks after CRT had a low rate of regional recurrence without ND. This study also suggests that lymph node residual size and percentage of regression on CT after CRT may be useful criteria to guide clinical decisions regarding neck surgery. Those results can help diminish the number of ND procedures with negative results and their associated surgical complications.
PURPOSE: The aim of this study was to describe the outcome in patients with head-and neck-squamous cell carcinoma (HNSCC) followed up without neck dissection (ND) after concomitant chemoradiotherapy (CRT) based on computed tomography (CT) response. The second objective was to establish CT characteristics that can predict which patients can safely avoid ND. METHODS AND MATERIALS: Between 1998 and 2007, 369 patients with node-positive HNSCC were treated with primary CRT at our institution. After a clinical and a radiologic evaluation based on CT done 6 to 8 weeks after CRT, patients were labeled with a complete neck response (CR) or with a partial neck response (PR). RESULTS: The median follow-up was 44 months. The number of patients presenting with N3, N2, or N1 disease were 54 (15%), 268 (72%), and 47 (13%), respectively. After CRT, 263 (71%) patients reached a CR, and 253 of them did not undergo ND. Ninety-six patients reached a PR and underwent ND. Of those, 34 (35%) had residual disease on pathologic evaluation. A regression of the diameter of ≥ 80% and a residual largest diameter of 15 mm of nodes had negative pathologic predictive values of 100% and 86%, respectively. The 3-year regional control and survival rates were not different between patients with CR who had no ND and patients with PR followed by ND. CONCLUSION: Node-positive patients presenting a CR as determined by CT evaluation 6 to 8 weeks after CRT had a low rate of regional recurrence without ND. This study also suggests that lymph node residual size and percentage of regression on CT after CRT may be useful criteria to guide clinical decisions regarding neck surgery. Those results can help diminish the number of ND procedures with negative results and their associated surgical complications.
Authors: J L Wichmann; J Kraft; E-M Nöske; B Bodelle; I Burck; J-E Scholtz; C Frellesen; J Wagenblast; J M Kerl; R W Bauer; T Lehnert; T J Vogl; B Schulz Journal: AJNR Am J Neuroradiol Date: 2014-08-07 Impact factor: 3.825
Authors: R Montal; M Oliva; M Taberna; L De Avila; A Rovira; M Cos; M Mañós; V Navarro; J Nogués; A Lozano; L Rodríguez; E Vilajosana; S Vázquez; R Mesia Journal: Clin Transl Oncol Date: 2016-03-10 Impact factor: 3.405
Authors: Thomas J Galloway; Qiang Ed Zhang; Phuc Felix Nguyen-Tan; David I Rosenthal; Denis Soulieres; André Fortin; Craig L Silverman; Megan E Daly; John A Ridge; J Alexander Hammond; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-28 Impact factor: 7.038
Authors: Chad Tang; Clifton D Fuller; Adam S Garden; Musaddiq J Awan; Rivka R Colen; William H Morrison; Steven J Frank; Beth M Beadle; Jack Phan; Erich M Sturgis; Mark E Zafereo; Randal S Weber; David I Rosenthal; G Brandon Gunn Journal: Oral Oncol Date: 2014-11-28 Impact factor: 5.337
Authors: Alfredo Páez-Carpio; Santiago Medrano-Martorell; Joan Berenguer; Africa Muxí; Isabel Vilaseca; Izaskun Valduvieco; Paola Castillo; Neus Baste; F Xavier Avilés-Jurado; Juan José Grau; Laura Oleaga Journal: Eur Arch Otorhinolaryngol Date: 2022-10-01 Impact factor: 3.236
Authors: J D Hamilton; S Ahmed; V C Sandulache; S P Daram; T J Ow; H D Skinner; A Rao; L E Ginsberg; A J Kumar; J N Myers Journal: AJNR Am J Neuroradiol Date: 2013-03-07 Impact factor: 3.825
Authors: Mark C Ranck; Rainier Abundo; Gina Jefferson; Antonia Kolokythas; Barry L Wenig; Ralph R Weichselbaum; Michael T Spiotto Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-01 Impact factor: 6.223
Authors: Charles Marcus; Anthony Ciarallo; Abdel K Tahari; Esther Mena; Wayne Koch; Richard L Wahl; Ana P Kiess; Hyunseok Kang; Rathan M Subramaniam Journal: J Nucl Med Date: 2014-06-19 Impact factor: 10.057